The Many Faces of Neovascular Retinal Disease: Who Is Eligible for Novel Treatment? is organized by Healio, Paradigm Medical Communications, LLC
Release Date: July 31, 2023
Expiration Date: July 31, 2024
Program Overview:
With the recent availability of a first-ever bispecific antibody for neovascular retinal disease treatment, anti-vascular endothelial growth factor (VEGF) is not necessarily the most appropriate therapy for patients with these progressive, high-burden diseases. How does novel therapy work? What is the evidence supporting its use? And which patients are good candidates? This spirited, expert-led lightning round will explore these questions and more across a variety of patients and disease states—with some friendly competition along the way.
Learning Objective
Upon completion of this activity, participants should be able to:
• Identify central components of the mechanisms of action of novel therapy that may help explain enhanced durability and improved anatomic outcomes versus anti-VEGF therapy in the treatment of neovascular retinal diseases
• Describe key characteristics of seminal studies of novel therapy versus anti-VEGF therapy in the treatment of neovascular retinal diseases, such as study populations, methodology, and findings
• Recognize patients with neovascular retinal diseases who would benefit from treatment with a novel therapy that addresses pathways beyond VEGF-A